Spain: Sublicense Agreement Almirall and Bicosome Enter into a Collaboration
Almirall, a global pharmaceutical company, and Bicosome, a start-up company that develops and commercializes high performance cosmetic and dermopharmaceutical ingredients, announced that they have entered into a research, collaboration and sublicense agreement.
Barcelona/Spain – The agreement concerns the development of multiple topical dermatological products, based upon Bicosome's proprietary patented delivery technology platform, Bicosome Technology.
In accordance with the terms of the agreement, Bicosome will be responsible for the research activities to deliver preclinical product prototypes using their proprietary encapsulating system and Almirall will perform the clinical development, regulatory filings, manufacturing and commercialization activities of the developed products.
Furthermore, Bicosome grants Almirall a sublicense to develop and commercialize products in certain dermatological indications. Bicosome will receive research payments and is entitled to potential development milestone payments as well as tiered royalties on future Net Sales and sales milestones.